OCU400 Second Eye Dosing

Preclinical

OCU400 Second Eye Dosing is one of 17 therapeutic programs targeting Retinitis Pigmentosa. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Retinitis PigmentosaActive, not recruiting

Retinitis PigmentosaPreclinical

Active, not recruiting

Competition

Competitive Landscape

25 competitors in Retinitis Pigmentosa

#DrugCompanyPhaseTrials

Trexall

Plaquenil

Lodosyn

Acetadote

AArbor Pharmaceuticals, Inc.

Approved

—5

Bendopa

MMerz North America, Inc.

Approved

—6

Cysteine Hydrochloride

Novartis

Phase 3

1 7

Minocin

TTriax

Phase 3

2 8

Neoral

BS01

1 10

Human Retinal Progenitor Cells

JjCyte, Inc

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

PreclinicalActive, not recruiting

Retinitis Pigmentosa

NCT05203939

Clinical

Trials by Indication[1]

Retinitis Pigmentosa1 trial

A Phase 1/2 Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa Associated With NR2E3 and RHO Mutations and Leber Congenital Amaurosis With Mutation(s) in CEP290 Gene

Active, not recruiting·OOcugen·Preclinical·NCT05203939·22 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for OCU400 Second Eye Dosing. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for OCU400 Second Eye Dosing. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Ocugen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: OOcugen

OCU400 Second Eye Dosing

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Retinitis Pigmentosa1 trial

References

Drug Info

Quick Facts

Related News